BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.19 | $0 | -$1M |
| 2025 Q4 | -0.22 | $0 | -$740,000 |
| 2025 Q3 | -0.19 | $0 | -$1M |
| 2025 Q2 | -0.34 | $0 | -$4M |
| 2025 Q1 | -0.45 | $0 | -$2M |
| 2024 Q4 | -0.52 | $0 | -$1M |
| 2024 Q3 | -0.51 | $0 | -$3M |
| 2024 Q2 | -0.54 | $0 | -$2M |